跳至主要内容
临床试验/NCT03484260
NCT03484260已完成不适用

Association Between the Prevalence of Cardiovascular Risk Factors and New Use of Testosterone

Bayer1 个研究点 分布在 1 个国家目标入组 27,778 人开始时间: 2018年4月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
27,778
试验地点
1
主要终点
Estimation of the association between cardiovascular risk factors and initiation of testosterone therapy

研究概览

简要总结

We will investigate if testosterone is preferentially given to patients at higher risk of cardiovascular events. If this is the case, then observational studies may be prone to selection bias resulting in overestimation of the cardiovascular risk associated with testosterone when compared to a healthier population not taking testosterone

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • All male individuals in the source population with a first testosterone use during the study period will be included as cases. The date of the GP consultation associated with the first testosterone prescription will be designated as the index day.

排除标准

  • Patients of less than 18 years on the index day, with less than 2-year contribution to the CPRD-HES link before the index day, or with use of testosterone before the study period will be excluded from the group of cases.

研究组 & 干预措施

Case group: Testosterone Product

Male subjects prescribed testosterone in UK

干预措施: Testosterone Product (Drug)

结局指标

主要结局

Estimation of the association between cardiovascular risk factors and initiation of testosterone therapy

时间窗: Retrospectively from 01 January 2001 to 31 March 2016

次要结局

未报告次要终点

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验